
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated strong revenue growth, reporting a year-over-year increase of 57% in new patient starts (NPS) alongside higher-than-expected performance in the pharmacy channel. The company's management has revised their revenue estimates for 2025 and 2026 upwards, projecting $97.5 million and $136 million, respectively, and has bolstered their 4Q25 revenue forecast to $29.8 million due to robust new prescription momentum and a solid durable medical equipment (DME) mix. With a significant portion of NPS coming from conversions of multiple daily injection patients and the successful expansion of sales territories, Beta Bionics appears well-positioned to maintain a premium growth profile with a projected compound annual growth rate (CAGR) of 30-40% from 2024 to 2028.
Bears say
Beta Bionics Inc. faces several critical challenges that contribute to a negative outlook on its stock, primarily surrounding its ability to capture market share with its iLet Bionic Pancreas amidst competitive pressures, which could adversely affect revenue and profitability. Additionally, the company may experience setbacks due to delays in clinical development timelines and the lack of an FDA marketing label, hindering the adoption of its products. Lastly, potential capital needs may lead to shareholder dilution, compounded by uncertain Medicare reimbursement policies that could impose further obstacles to the company's growth trajectory.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares